MICHAEL FANG, YUNWEN XU, JOSEF CORESH, SHOSHANA BALLEW, ELIZABETH SELVIN, JUNG-IM SHIN
{"title":"1444-P: Trends and Disparities in Continuous Glucose Monitoring Use in U.S. Youth and Adults with Type 1 Diabetes—2008–2022","authors":"MICHAEL FANG, YUNWEN XU, JOSEF CORESH, SHOSHANA BALLEW, ELIZABETH SELVIN, JUNG-IM SHIN","doi":"10.2337/db24-1444-p","DOIUrl":null,"url":null,"abstract":"Introduction: Continuous glucose monitoring (CGM) technology has revolutionized the management of type 1 diabetes. However, trends and disparities in CGM use remain poorly characterized in general type 1 diabetes population. Methods: We conducted a serial cross-sectional analysis of youth and adults with type 1 diabetes using de-identified electronic health record data from the Optum Labs Data Warehouse. Type 1 diabetes status was determined using a validated algorithm. Use of CGM was ascertained by National Drug Codes from prescription order data. We examined trends in CGM use from 2008-2010 to 2020-2022, overall and by age, sex, race/ethnicity, and insurance type. Results: We included 128,821 individuals with type 1 diabetes (17% under age 18 years; 48% female; 78% non-Hispanic White). From 2008-2010 to 2020-2022, the use of CGM increased from <1% to 47% in youth and 2% to 37% in adults with type 1 diabetes (Fig A1 and A2). Uptake of CGM was similar across age and sex, but substantially lower in racial/ethnic minority patients and those with Medicaid insurance (Fig B1-E2). Conclusion: Over the past 15 years, the use of CGM has grown significantly among persons with type 1 diabetes in the US. However, racial/ethnic and socioeconomic disparities have widened in both youth and adults. There is an urgent need to expand access to care and diabetes technology to improve care in this population. Disclosure M. Fang: None. Y. Xu: None. J. Coresh: Consultant; SomaLogic, Healthy.io. S. Ballew: None. E. Selvin: None. J. Shin: None. Funding K01 DK138273-01","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":null,"pages":null},"PeriodicalIF":6.2000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-1444-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Continuous glucose monitoring (CGM) technology has revolutionized the management of type 1 diabetes. However, trends and disparities in CGM use remain poorly characterized in general type 1 diabetes population. Methods: We conducted a serial cross-sectional analysis of youth and adults with type 1 diabetes using de-identified electronic health record data from the Optum Labs Data Warehouse. Type 1 diabetes status was determined using a validated algorithm. Use of CGM was ascertained by National Drug Codes from prescription order data. We examined trends in CGM use from 2008-2010 to 2020-2022, overall and by age, sex, race/ethnicity, and insurance type. Results: We included 128,821 individuals with type 1 diabetes (17% under age 18 years; 48% female; 78% non-Hispanic White). From 2008-2010 to 2020-2022, the use of CGM increased from <1% to 47% in youth and 2% to 37% in adults with type 1 diabetes (Fig A1 and A2). Uptake of CGM was similar across age and sex, but substantially lower in racial/ethnic minority patients and those with Medicaid insurance (Fig B1-E2). Conclusion: Over the past 15 years, the use of CGM has grown significantly among persons with type 1 diabetes in the US. However, racial/ethnic and socioeconomic disparities have widened in both youth and adults. There is an urgent need to expand access to care and diabetes technology to improve care in this population. Disclosure M. Fang: None. Y. Xu: None. J. Coresh: Consultant; SomaLogic, Healthy.io. S. Ballew: None. E. Selvin: None. J. Shin: None. Funding K01 DK138273-01
期刊介绍：
Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes.
However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
